Literature DB >> 35359575

Clinical and Functional Features of Epilepsy-Associated In-Frame Deletion Variants in SCN1A.

Jing-Yang Wang1,2,3, Bin Tang1,2, Wen-Xiang Sheng1,2, Li-Dong Hua4, Yang Zeng1,2, Cui-Xia Fan1,2, Wei-Yi Deng1,2, Mei-Mei Gao1,2, Wei-Wen Zhu3, Na He3, Tao Su1,2.   

Abstract

Objective: Naturally occurring in-frame deletion is a unique type of genetic variations, causing the loss of one or more amino acids of proteins. A number of in-frame deletion variants in an epilepsy-associated gene SCN1A, encoding voltage gated sodium channel alpha unit 1.1 (Nav1.1), have been reported in public database. In contrast to the missense and truncation variants, the in-frame deletions in SCN1A remains largely uncharacterized.
Methods: We summarized the basic information of forty-four SCN1A in-frame deletion variants and performed further analysis on six variants identified in our cases with epilepsy. Mutants of the six in-frame deletions and one truncating variant used as comparison were generated and co-transfected with beta-1 and -2 subunits in tsA201 cells, followed by patch clamp recordings.
Results: Reviewing all the in-frame deletions showed that they spread over the entire Nav1.1 protein, without obvious "hot spots." The dominant type (54%) was single residue loss. There was no obvious relationship between the length or locations of deletions and their clinical phenotypes. The six in-frame deletions were two single residue deletions (p.M400del and p.I1772del), one microdeletion (p.S128_F130del) and three macrodeletions (p.T303_R322del, p.T160_Y202del, and p.V1335_V1428del). They scatter and affect different functional domains, including transmembrane helices, pore region, and P-loop. Electrophysiological recordings revealed no measurable sodium current in all of the six mutants. In contrast, the truncating mutant p.M1619Ifs*7 that loses a long stretch of peptides retains partial function. Significance: The complete loss-of-function in these shortened, abnormal mutants indicates that Nav1.1 protein is a highly accurate structure, and many of the residues have no redundancy to ion conductance. In-frame deletions caused particularly deleterious effect on protein function possibly due to the disruption of ordered residues.
Copyright © 2022 Wang, Tang, Sheng, Hua, Zeng, Fan, Deng, Gao, Zhu, He and Su.

Entities:  

Keywords:  SCN1A; epilepsy; in-frame deletion; sodium channel; variant

Year:  2022        PMID: 35359575      PMCID: PMC8964123          DOI: 10.3389/fnmol.2022.828846

Source DB:  PubMed          Journal:  Front Mol Neurosci        ISSN: 1662-5099            Impact factor:   5.639


Introduction

Voltage-gated sodium channels (Nav) are responsible for the generation and propagation of action potentials in excitable membrane. These channels are complexes of one α subunit in association with two auxiliary β subunits. In humans, there are nine functional α subunits (Nav1.1-Nav1.9) encoded by the genes SCN1A-SCN11A, with different patterns of tissue expression and biophysical properties. The α subunit of ∼2000 amino acid (AA) residues is organized in four homologous domains but non-identical domains (DI-DIV), each of which contains six transmembrane segments (S1–S6) and an additional membrane re-entrant pore loop (P-loop). Four transmembrane domains (DI–DIV) are connected by intracellular loop structures (Catterall, 2000; Goldin et al., 2000; Eijkelkamp et al., 2012). Variants in the gene SCN1A encoding Nav1.1 α subunit have been associated with a spectrum of epilepsy disorders ranging from the relatively benign generalized epilepsy with febrile seizures plus (GEFS+) to the devastating disorder, severe myoclonic epilepsy of infancy (SMEI) (Escayg et al., 2000, 2001; Marini et al., 2009). To date, more than 1,800 epilepsy associated variants annotated for SCN1A have been reported in different databases, such as SCN1A database[1], the Human Gene Mutation Database (HGMD), and the ClinVar database of NCBI. Most of these are missense variants that lead to a single amino acid substitution, while there are also a significant number of in-frame deletions and premature truncations that lacks one or more amino acids. Previous studies focused on characterizing the biophysical properties of missense and truncating variants (Lossin et al., 2003; Yamakawa, 2006; Meng et al., 2015). The in-frame deletions occurred in SCN1A have not been well characterized, except that an in-frame deletion (p.F1289del), located at DIII S3, was reported with no measurable sodium current (Ohmori et al., 2006). The naturally occurring in-frame deletions would be unique and useful models to explore the underlying biology of Nav1.1, and the genotype-phenotype relationship as well. Here we first collected a total of 44 in-frame deletion variants in SCN1A from the HGMD and SCN1A database and characterized their features of clinical phenotypes and locations. To gain insights into sub-molecular gating network of Nav1.1, six in-frame deletions identified in our laboratory were further subject to site-directed mutagenesis experiments to determine the functional features of the shortened Nav1.1.

Materials and Methods

Public Data Collection

All available in-frame deletion variants in SCN1A (a total of 44 variants) were retrieved from the SNP database of the NCBI[2], the SCN1A database (see text footnote 1) and the HGMD. The NCBI database was queried with amino acid sequences of human Nav1.1 to obtain the corresponding information of DNA locus, and related functional regions.

Genetic Testing

Diagnose and treatments of the patients were conducted in our Epilepsy Center (Guangzhou, China). Clinical data including medical records, standardized questionnaires, and EEG recordings were available. The probands were assessed using a standardized protocol after providing written informed consent. This study was approved by the Research Ethics Board of the Hospital. Genomic DNAs were prepared from ethylenediaminetetraacetic acid (EDTA)-treated whole blood samples. SCN1A were screened for genetic abnormalities. Primers were designed to amplify all exons and the flanking intronic splice sites of the gene. The purified PCR products of polymerase chain reaction were directly sequenced. The variant was verified by a second targeted PCR and sequencing. A total of six in-frame deletion variants in SCN1A were identified in our genetic testing, among which three were novel and three variants (c.383 + 1A > G/p.S128_F130del, c.602 + 1G > A/p.T160_Y202del, and c.1200_1202delGAT/p.M400del) were previously reported (Depienne et al., 2009; Selmer et al., 2009).

Mutagenesis and Heterologous Expression

To reconstitute the native brain sodium channel complex, SCN1A was co-expressed heterologously with human accessory β1 and β2 subunits in human tsA201 cells. The expression vectors of wild-type (WT) human sodium channel Nav1.1, pCMV-SCN1A-WT, pCD8-IRES-hβ1, and pGFP-IRES-hβ2 that express α, β1, and β2 subunits, were kindly donated by Professor Alfred L. George Jr. To improve the monitoring of transfection, pCD8-IRES-hβ1 had been modified into pDsred-IRES-hβ1 with red fluorescence; whereas pGFP-IRES-hβ2 expression is recognized by green fluorescence. The mutant vectors were generated from corresponding WT vectors using Quick-change site-directed mutagenesis (Stratagene, Cedar Creek, TX, United States) according to the manufacturer’s protocol. All constructs were verified by resequencing before being transfected to human tsA201 cells. The cells were grown in 1:1 Ham’s F-12 and Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml of penicillin, and 100 μg/ml streptomycin. The cells were maintained in a humidified incubator at 37°C with 5% CO2. Cells were then co-transfected with pCMV-SCN1A, pCD8-IRES-hβ1, and pGFP-IRES-hβ2, using Lipofectamine 3000 reagent Kit from Thermo Fisher Scientific. After incubation for 12–15 h, cells were replated in 35-mm culture dishes.

Patch Clamp Analysis

Electrophysiological studies were performed 20–48 h after transfection, according to our previous report (Chen et al., 2015). Cells displaying green and red fluorescence were chosen for recording. According to our previous experience, almost all the cells (>90%) that had green and red fluorescence were expressing a complex of co-transfected α, β1 and β2 subunits. Whole-cell patch clamp was performed according to previous reports. Sodium currents were recorded from tsA201 cells at room temperature (22–24°C). Series resistance (2.0–3.0 MΩ) was compensated 85–95% to assure that the command potential was reached within microseconds and with a voltage error of <4 mV. All data were acquired at 10–50 kHz and low-pass filtered at 5 kHz. The pipette solution contained (in mM): NaF 10, CsF 110, CsCl 20, EGTA 2, and HEPES 10, with a pH of 7.35 and osmolarity of 310 mOsM/kg. The extracellular solution contained (in mM): NaCl 145, KCl 4, CaCl2 1.8, MgCl2 1, and HEPES 10, with a pH of 7.35 and osmolarity of 310 mOsM/kg. Sodium currents were recorded with EPC10 amplifiers (HEKA Elektronik, Lambrecht, Germany). Sodium currents were recorded at various test potentials from a holding potential of −120 mV. The inward currents were validated by Nav blocker tetrodotoxin. Sodium conductance (G) was calculated according to the equation G = Ipeak/(Vtest-Vrev), where Ipeak is the peak inward current, Vtest is the test potential, and Vrev is the reversal potential for Na+. To compare voltage dependence of activation, data were fitted to a Boltzmann function, according to the equation G/Gmax = 1−1/{1 + exp[(Vm–V1/2)/k]}, where Gmax is the maximum conductance, Vm is the potential of individual step pulses, V1/2 is the average half activation potential (at which G is one-half maximal), and k is the slope factor. The voltage dependence of channel availability was assessed following a prepulse to various potentials followed by 20-ms pulse to −10 mV. The normalized current was plotted against the voltage and the inactivation curves were fit with Boltzmann functions (I/Imax = 1/(1 + exp[(Vm−V1/2)/k]) to determine the voltage for half-maximal channel inactivation (V1/2) and slope factor (k). Recovery from inactivation was determined using a two-pulse protocol. The peak current from the test pulse was normalized to the peak current from a prepulse and plotted against the recovery period. Data were fit with the two exponential function, I/Imax = Af [1−exp(−t/τf)] + As [1−exp(−t/τs)], where τf and τs denote time constants (fast and slow components, respectively).

Structural Modeling

The structures of the WT Nav1.1 and fragmental peptides (about 600 AA, deletion locus was covered) of the deletion variants were modeled to predict the effect of deletion mutations on protein structure by using I-Tasser[3]. PyMOL 2.3 software was used for three-dimensional protein structure visualization and analysis.

Statistical Analysis

All data were analyzed using a combination of Fit master v2.53 (HEKA Electronics, Lambrecht, Germany), Excel 2003 (Microsoft, Seattle, WA, United States), and OriginPro 8.0 (OriginLab, Northampton, MA, United States) software. For statistical evaluation, results are shown as means ± SEM, and differences between WT and mutant channels were assessed by Student’s t-test. One-way analysis of variance (ANOVA) was used to compare means among different groups. Significance was assigned at P < 0.05.

Results

Features of In-Frame Deletion Variants in SCN1A

Six in-frame deletions in SCN1A were identified in our cases with SMEI, generalized epilepsy with febrile seizures plus (GEFS+), partial epilepsy with febrile seizures plus (PEFS+) and Lennox–Gastaut syndrome (LGS) (Table 1). One variant (c.383 + 1A > G/p.S128_F130) associated with LGS and two variants (c.602 + 1G > A/p.T160_Y202del and c.1200_1202delGAT/p.M400del) associated with SMEI were reported in the ClinVar database or previous studies (Depienne et al., 2009; Selmer et al., 2009), while the other variants were novel. Residues affected by these variants are located in several distinct protein domains including the DI/S1 (c.383 + 1A > G/p.S128_F130del), DI/S2-S3 (c.602 + 1G > A/p.T160_Y202del), pore loop in DI (c.909A > G/p.T303_R322del, c.1200_1202delGAT/p.M400del), cytoplasmic DIII/S4-S5 linker to pore loops in DIII (c.4284 + 2T > C/p.V1335_V1428del), and DIV/S6 (c.5313_5315delCAT/p.I1772del) (illustrated in Figure 1).
TABLE 1

Clinical features associated with six identified in-frame deletion and one truncation variants in SCN1A.

MutationMutation positionAge at FS/aFS onsetSeizure typeInheritedDiagnosisEEGMental retardationAEDsPROVEAN
c.383 + 1A > G/p.S128_F130delDIS1 (Intron 2)NAMyo, Tonic, Atonic, CPS, GTCS De novo LGSGSW, FSWSevere learning disabilityVPA+LTG+PT(∧)D
c.602 + 1G > A/p.T160_Y202delDIS2-S3 (Exon 4)8 m/2 yearssGTCS, CPS De novo DSFSWNormalVPA+TPM(↓)D
c.909A > G/p.T303_R322delDIS5-S6 (Exon 6)2 years/−GTCS De novo FS+NANormalNAD
c.1200_1202delGAT/p.M400delDIS6 (Exon 9)8 m/−GTCS, CPS De novo DSGSW, FSWSpeech defectVPA+LEV(↓)D
c.4284 + 2T > C/p.V1335_V1428delDIIIS5-S6 (Exon 21)6 m/6 mMyo, CPS, sGTCSPaternalDSGSW, FSWNormalVPA+TPM(∧)D
c.5313_5315delCAT/p.I1772delDIVS6 (Exon 26)7 m/3 yearsGTCS, CPS De novo PEFS+NormalModerateVPA+CNZ(↓)D
c.4853-25T > A/p.M1619Ifs*7DIVS3 (Exon 26)18 m/5 yearsGTCS, CPSMaternalPEFS+NANANAD

CPS, complex partial seizures; GTCS, generalized tonic-clonic seizures; Myo, myoclonic seizures; Tonic, tonic seizure; Atonic, atonic seizures; LGS, Lennox-Gastaut syndrome; GSW, generalized spike waves; FSW, focal spike waves; NA, not available; VPA, valproic acid; LTG, lamotrigine; TPM, topiramate; LEV, levetiracetam; CNZ, clonazepam; D, deleterious. (∧), seizure-free; (↓), seizure remission.

FIGURE 1

Locations of six in-frame deletion and one truncating variants in SCN1A and sequence identification. (A) Schematic location of the variants identified. The in-frame deletion variants were marked with dotted lines and the truncating variant was marked with a scissor. (B) DNA sequencing of the truncating variant (c.4853-25T > A/p.M1619Ifs*7). (C) DNA sequencing of the in-frame deletion variants.

Clinical features associated with six identified in-frame deletion and one truncation variants in SCN1A. CPS, complex partial seizures; GTCS, generalized tonic-clonic seizures; Myo, myoclonic seizures; Tonic, tonic seizure; Atonic, atonic seizures; LGS, Lennox-Gastaut syndrome; GSW, generalized spike waves; FSW, focal spike waves; NA, not available; VPA, valproic acid; LTG, lamotrigine; TPM, topiramate; LEV, levetiracetam; CNZ, clonazepam; D, deleterious. (∧), seizure-free; (↓), seizure remission. Locations of six in-frame deletion and one truncating variants in SCN1A and sequence identification. (A) Schematic location of the variants identified. The in-frame deletion variants were marked with dotted lines and the truncating variant was marked with a scissor. (B) DNA sequencing of the truncating variant (c.4853-25T > A/p.M1619Ifs*7). (C) DNA sequencing of the in-frame deletion variants. We summarized all the in-frame deletion variants (a total of 44, together with the six variants identified by us) from the databases, and found that most of them (38/44) were reported as SMEI, developmental and epileptic encephalopathy (DEE) and LGS (Table 2). These variants spread over six functional domains of Nav1.1 (Figures 2A,B). Approximately 54% of the in-frame deletions are single deletions of 1 AA, followed by microdeletions (2–6 AA, 30%) and macrodeletions (>6 AA, 16%) (Figure 2C). Almost all the single deletions are associated with SMEI, DEE, except of one in DIV/S6 presented with PEFS+ Figure 2D). One microdeletion located in DI S5-S6 linker is associated with febrile seizure plus (FS+). There is no clear relationship between clinical phenotypes and the length of deletions.
TABLE 2

In-frame deletion variants of SCN1A.

VariantLength (AA)PositionPhenotypeReferences
p.Phe17del1N terminalDS Zuberi et al., 2011
p.Thr18del1N terminalDS Djemie et al., 2016
p.Gly58_Leu61del4N terminalDS https://ncbi.nlm.nih.gov/clinvar/
p.Leu80_Asp81del2N terminalDS Usluer et al., 2016
p.Ile99_Ala104del6N terminalDS Gonsales et al., 2019
p.Leu129del1DI S1DS Mancardi et al., 2006
p.Ser128_Phe130del3DI S1LGS Selmer et al., 2009
p.Leu129_Glu158del30DI S1, S1-S2, S2DS https://./clinvar/
p.Thr160_Tyr202del43DI S2, S2-S3, S3DS https://./clinvar/
p.Glu181del1DI S2-S3DS Till et al., 2020
p.Asp208_Arg219del12DI S3-S4, S4DS de Lange et al., 2018
p.Lys246del1DI S4-S5DS Peng et al., 2019
p.Leu247del1DI S4-S5Ep or NDD Lindy et al., 2018
p.Thr303_Arg322del20DI S5-S6FS+
p.Tyr325del1DI S5-S6DS Wu et al., 2015
p.Met400del1DI S6DS Depienne et al., 2009
p.Thr775del1DII S1DS Aljaafari et al., 2017
p.Met815del1DII S2DEE https://./clinvar/
p.Gly854_Leu855del2DII S3-S4DS Zuberi et al., 2011
p.Lys868del1DII S4DS Moehring et al., 2013
p.Val896_Ala898del3DII S5Ep or NDD Lindy et al., 2018
p.Met960_Cys968del9DII S5-S6, S6DS Yang et al., 2017
p.Thr1210del1DII-DIII linkerDS http://SCN1A.caae.org.cn/by_mutation.php
p.Ile1240_Asp1243del4DIII S1-S2DEE https://./clinvar/
p.Thr1247_Thr1250del4DIII S1-S2DS http://SCN1A.caae.org.cn/by_mutation.php
p.Phe1289del1DIII S3DS Depienne et al., 2009
p.Val1335_V1428del94DIII S4-S5, S5, S5-S6DS
p.Ala1429del1DIII S5-S6DS Zuberi et al., 2011
p.Asn1446_Gly2008del563DIII S5-S6, S6, DIII-DIV, DIV, C-terminalDS https://./clinvar/
p.Phe1473del1DIII S6DS Depienne et al., 2009
p.Ile1483del1DIII S6DS Depienne et al., 2009
p.Glu1503del1DIII-DIV linkerDS Wang et al., 2012
p.Met1558del1DIV S1DS Fukuma et al., 2004
p.Met1559del1DIV S1DS Fukuma et al., 2004
p.Val1560_Thr1562del3DIV S1-S2DS Brunklaus et al., 2020
p.Asn1672del1DIV S4-S5DS Gertler et al., 2020
p.Gly1674_Leu1675del2DIV S5Ep or NDD Lindy et al., 2018
p.Phe1766del1DIV S6DS Fukuma et al., 2004
p.Ile1772del1DIV S6PEFS+
p.Met1807_Glu1810del4C terminalDS Fujiwara et al., 2003
p.Glu1813_Phe1815del3C terminalDS Depienne et al., 2009
p.Leu1835_Pro1837del3C terminalEp or NDD Lindy et al., 2018
p.Thr1909del1C terminalDS Zuberi et al., 2011
p.Gln1914del1C terminalRefractory epilepsy Liu et al., 2018

DS, Dravet syndrome (SMEI); Ep, epilepsy; NDD, neurodevelopmental disorders; LGS, Lennox–Gastaut syndrome; PEFS+, partial epilepsy with febrile seizures plus; FS+, Febrile seizures plus.

FIGURE 2

Statistics of all in-frame deletions in SCN1A. (A) Schematic picture showing the length, location, and phenotypes of the 44 variants. Lines indicate different variants. Severe phenotypes (SMEI, DEE, and LGS) were highlighted as red, while mild phenotypes (PEFS+ and FS+) were blue. (B) Distribution of the variants on different functional domains. (C) The proportions of single deletion, microdeletions, and macrodeletions. (D) Phenotypic spectrum.

In-frame deletion variants of SCN1A. DS, Dravet syndrome (SMEI); Ep, epilepsy; NDD, neurodevelopmental disorders; LGS, Lennox–Gastaut syndrome; PEFS+, partial epilepsy with febrile seizures plus; FS+, Febrile seizures plus. Statistics of all in-frame deletions in SCN1A. (A) Schematic picture showing the length, location, and phenotypes of the 44 variants. Lines indicate different variants. Severe phenotypes (SMEI, DEE, and LGS) were highlighted as red, while mild phenotypes (PEFS+ and FS+) were blue. (B) Distribution of the variants on different functional domains. (C) The proportions of single deletion, microdeletions, and macrodeletions. (D) Phenotypic spectrum.

In-Frame Deletion Mutants Exhibit Complete Loss-of-Function

The WT and six in-frame deletion mutant alpha-subunits were expressed transiently in human tsA201 cells. We performed electrophysiological recordings for the transfected neurons and the non-transfected neurons as negative control. In contrast to the WT Nav1.1 with apparent current recorded (>90 pA/pF), the six in-frame deletion mutants all exhibited tiny raw currents (usually <20 pA/pF) (Figures 3A,B). The tiny currents were demonstrated as endogenous current, which was also recorded in non-transfected cells. Therefore, we confirmed that the in-frame deletion mutants were not able to generate Na+ current and fail to exhibit sufficient sodium current for biophysical analysis.
FIGURE 3

Electrophysiological analysis of the SCN1A in-frame deletion and truncated mutants. (A) Representative traces of sodium current evoked at 0 mV. (B) Current-voltage relationship of six in-frame deletion mutants. (C) Current-voltage relationship of the truncated mutant. (D) G-V activation curve, (E) steady-state inactivation curve, and (F) recovery from inactivation, all for the truncated mutant p.Met1619Ilefs*7. Non-transfected cells were used as negative control.

Electrophysiological analysis of the SCN1A in-frame deletion and truncated mutants. (A) Representative traces of sodium current evoked at 0 mV. (B) Current-voltage relationship of six in-frame deletion mutants. (C) Current-voltage relationship of the truncated mutant. (D) G-V activation curve, (E) steady-state inactivation curve, and (F) recovery from inactivation, all for the truncated mutant p.Met1619Ilefs*7. Non-transfected cells were used as negative control.

A Truncated Mutant Retains Partial Channel Function

We noticed that the in-frame deletion mutant causing a single loss of isoleucine at the S6 of DIV (I1772) resulted in complete loss-of-function. This raised an interesting question about whether a truncation mutant that was much shortened still functioned. A truncating variant c.4853-25T > A/p.M1619Ifs*7 was previously identified in our patient with PEFS+. The premature truncation is expected to have seven AA substitutions from p.M1619-E1626, with a loss of peptides from S3 of DIV to c-terminal. Interestingly, the truncated mutant exhibited partial loss-of-function, with reduced peak current density (−27.47 ± 8.46 pA/pF vs. −116.60 ± 25.60 pA/pF in the WT control, 23.6% of the WT) (Figure 3C and Table 3). The current-voltage relation analysis showed that the p.M1619Ifs*7 mutant exhibited a less steep conductance-voltage (G-V) curve with the smaller slopes of steady-state availability, but remained unchanged in the half-maximal activation and inactivation (V1/2), suggesting a slight disruption of the voltage sensor (Figures 3D,E and Table 3). There was no significant difference in the time constants in the kinetics of recovery from inactivation (Figure 3F and Table 3).
TABLE 3

Biophysical parameters of truncating mutant p.Met1619Ilefs*7.

WT (n = 9)p.Met1619Ilefs*7 (n = 6)
Current density (−10 mv)pA/pF−116.60 ± 25.60−27.47 ± 8.46§
Voltage-dependence of activationV1/2 (mV)−26.10 ± 4.70−32.32 ± 25.86
k4.50 ± 0.157.31 ± 0.73§§
Voltage-dependence of fast inactivationV1/2 (mV)−54.42 ± 15.78−66.03 ± 31.03
k6.60 ± 0.259.70 ± 0.42§§
Recovery from fast inactivationτf (ms)1.06 ± 0.961.24 ± 1.11
τs (ms)23.94 ± 9.43168.86 ± 103.49

Compared with the WT,

Biophysical parameters of truncating mutant p.Met1619Ilefs*7. Compared with the WT,

Structure Modeling

To explore structural changes as a result of the in-frame deletions, we performed tertiary structure prediction. The comparative analysis of the predicted structures showed that the local tertiary folding differed strongly between the WT and mutants, especially for the macrodeletions (p.T303_R322del, p.T160_Y202del, and p.V1335_V1428del). The local structures of the macrodeletion mutants were deformed and the surrounding segments were relocated (Figure 4). The p.T160_Y202del deletion with two transmembrane segments involved has the most remarkable difference in protein folding, in which the expected segments (S2 and S3) disappear and moreover the adjacent S1 and S4 are relocated to the different sites. Both the single deletion (p.M400del) and microdeletion (p.S128_F130del) that have lost their hydrophobic residues including isoleucine, methionine and phenylalanine, were predicted to turn the coiled coil alpha helices into flexible loops. The other deletion (p.I1772del) at S6 exhibited a smaller difference in the alpha helix, but had a larger difference in the angle of the neighboring units compared to the WT.
FIGURE 4

Pairwise comparison of the predicted local structure features between wild-type and in-frame deletions. Location of deleted residues is indicated in blue, and their next residues are in red.

Pairwise comparison of the predicted local structure features between wild-type and in-frame deletions. Location of deleted residues is indicated in blue, and their next residues are in red.

Discussion

Genetic defects in the Nav α subunit can lead to various excitability diseases in brain, muscle, and heart, such as muscle paralysis, cardiac arrhythmias, and epileptic disorders (Meisler and Kearney, 2005; Lee et al., 2009; Remme and Bezzina, 2010; Kasperaviciute et al., 2013). The particular importance of Nav1.1 channel has continually motivated researchers to identify structural or functional residues responsible for protein stability and activity. So far, more than 1800 SCN1A variants have been identified in epilepsy, but few studies have investigated the function of these genetic defects. Functional analysis in coding regions of Nav1.1 channel might help to gain insights into the intramolecular gating network. In this study, we report the phenotypic relevance and biophysical characterization of seven SCN1A variants, including six SCN1A in-frame deletions and one truncating variant. The six in-frame deletions scatter and affect different functional domain, including transmembrane helices, pore region, and P-loop. There are two single residue deletions (p.M400del, p.I1772del), one microdeletion (p.S128_F130del) and three macrodeletions (p.T303_R322del, p.T160_Y202del, and p.V1335_V1428del). In accordance to the features of all in-frame deletion variants summarized from public databases, the six deletion variants were associated with severe phenotypes such as SMEI, DEE, and LGS, except that two cases presented with milder phenotypes, FS+ and PEFS+. In spite of different locations, residue length of deletions, and associated phenotypes, the six in-frame deletion mutants were found to consistently lose their ion conductance, showing barely detectable inward sodium currents in the heterologous expression experiments. It is conceivable that the macrodeletions with the loss of a large stretch of peptides would have impact on protein structure and serious functional effect. By contrast, the fact that the microdeletion and single deletion mutants also resulted in the complete loss-of-function is more striking, especially for the two single deletions (p.M400del and p.I1772del) locating at transmembrane domain DIV/S6. Analogous to p.I1772del, an in-frame deletion in the identical DIV/S6 in Nav1.6 (p.I1750del), which is a spontaneous mouse variant, was reported to be associated with a chronic movement disorder with early onset tremor and adult onset dystonia (Jones et al., 2016). The removal of isoleucine in mouse Nav1.6 also exhibited no measurable current in the functional studies (Jones et al., 2016). In addition, no measurable current was previously reported in a DS-associated in-frame deletion variant p.F1289del (Thompson et al., 2012), in which phenylalanine in the transmembrane segment DIII/S3 in Nav1.1 was removed. In our case, the microdeletion p.S128_F130del with a combined loss of phenylalanine, leucine, and serine in S1 led to complete loss-of-function. These transmembrane residues, including isoleucine, methionine, phenylalanine and leucine are all hydrophobic and critical for the interaction between transmembrane helices and lipid membrane. However, an exceptional case was found in an in-frame deletion of leucine (p.L955del) within DII/S6 of Nav1.7, which showed a gain-of-function with a robust hyperpolarizing shift of activation and slow inactivation (Yang et al., 2013). More efforts are needed to understand the functional architecture of voltage-gated sodium channels. The variant p.T303_R322del is expected to shorten the membrane-reentrant P-loop rather than affect transmembrane helices. The P-loop is the linker between S5 and S6, forming a selectivity filter—a narrow pathway that determines which ion will pass the pore (Catterall et al., 2007; Yang et al., 2009). Functional loss in the p.T303_R322del mutant indicates the non-redundant role of the P-loop for ion conductance. In support of this postulation, it was shown that a five amino acids in-frame deletion of P-loop in a p.R1370-L1374del of Nav1.7, which is associated with channelopathy-associated insensitivity to pain disorder, also resulted in a normally expressed but non-functional channel (Cox et al., 2010). Likewise in Nav1.5, a heterozygous in-frame deletion p.N1380del that was associated with cardiac conduction disturbance and ventricular tachycardia exhibited no detectable current (Yang et al., 2017), even though only a single amino acid was removed. Together with previous experimental mutagenesis and clinical studies (Terlau et al., 1991; Favre et al., 1996; Ishii et al., 2017), it has well established that P-loops are critical determinants of catalytic permeation properties of Na+ channels, but their precise structure-function and deletion-phenotype relationships remain largely unknown. The most puzzling result in the study is that the truncating mutant (p.M1619Ifs*7), that is expected to delete the S4–S6 pore-forming segments in DIV and the whole C-terminal tail, retained partial channel function. According to several expression and functional studies in the truncated Nav, most of the truncation variants would fail to produce functional channel (e.g., hNav1.1-p.R1234*), except those occurring at the C-terminal tail (e.g., hNav1.1-p.R1892*, hNav1.5-p.R1860Gfs*12) (Sugawara et al., 2003; Bechi et al., 2012; Brunklaus et al., 2020). However, the Na+ current in the p.M1619Ifs*7 transfected cell was observed in this study, although the current remarkably decreased to 24% of the WT. The evidence proved that the truncated channel without last pore-forming segments still retained the basic biophysics of Nav1.1. A possible explanation could be that new assembly of the remaining segments is capable of forming a functional channel. Several mechanisms might underlie the non-functional Nav1.1 channel. First, as Nav channel opening is determined by a series of gating checkpoints in the transmembrane and cytosolic regions, disruptions caused by missense or deletion variants at these gating checkpoints would definitely impact on the functioning of Nav1.1 channel. For example, the residues in the pore regions are highly conservative and determine ion selectivity and permeation, and the voltage-sensing domains determine the right response to membrane potential. Secondly, integrity of the functional motifs that determine mRNA expression, splicing, and protein trafficking has been destroyed. Thirdly, a local misfolding of residues disturbs the topology of the adjoining functional motifs and misleads gating motions. In our study, p.T303_R322del, p.M400del, p.V1335_V1428del, and p.I1772del affect the integrity of the pore-forming regions. This is consistent with the roughly loss-of-function changes found in missense variants in these gate checkpoints (Ohmori et al., 2006). However, both p.S128_F130del and p.T160_Y202del transformed the α helices into flexible loops according to the structural modeling (Figure 4), which would have impacts on overall arrangements of different segments. As functional motifs of a protein are usually a fixed order of the residues, deletions could be at higher risk of disrupting the order, thereby causing more deleterious effects on function or structure, when compared to missense or truncation mutations. It has been suggested that changes in amino acid sequence have variable functional effects on sodium channels, with a mixture of loss-of-function and gain-of-function effects (Yamakawa, 2006; Gataullina and Dulac, 2017). The SMEI-associated SCN1A variants seem to be more closely correlated with haploinsufficiency for Nav1.1, which caused by deleterious nonsense and frameshift variants in SCN1A (Gambardella and Marini, 2009; de Jonghe, 2011), and missense variants exhibiting remarkably attenuated or barely detectable sodium currents (Sugawara et al., 2003). Studies on heterozygous SCN1A± mice demonstrated that substantially reduced Na+ current density with a loss of sustained high-frequency firing of action potentials were found in hippocampal and cortical interneurons, possibly responsible for the spontaneous seizure phenotypes in the SCN1A± mice (Yu et al., 2006). In agreement with the previous result, the six in-frame deletion mutants in this study were non-functional and mostly associated with SMEI, except that two variants, p.T160_Y202del and p.I1772del, which affect pore regions, were associated with FS+ and PEFS+, respectively. The variable phenotypes might be explained by the role of genetic modifiers and molecular interactions. It remains a challenging conundrum for researchers about how the common loss-of-function in Nav1.1 results in different phenotypes. This study provides some new insights into the effect of in-frame deletion on the biological functions of Nav1.1, suggesting a complete loss-of-function of channel and their associations with clinical phenotypes including SMEI, FS+, and PEFS+. However, we only characterized the functional properties in the six out of 44 in-frame deletions identified to date. With more deletion variants identified and functionally characterized, the relationship among deletion pattern, functional changes, and clinical phenotypes would become more clear.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics Statement

The studies involving human participants were reviewed and approved by Ethics Committee of The Second Affiliated Hospital of Guangzhou Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author Contributions

TS and NH contributed to the conceptualization and funding acquisition. TS and J-YW designed the study, while the other authors performed the experiments and/or analyzed the data, and contributed to the manuscript draft. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
  51 in total

Review 1.  Sodium channel (dys)function and cardiac arrhythmias.

Authors:  Carol Ann Remme; Connie R Bezzina
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 2.  Molecular genetics of Dravet syndrome.

Authors:  Peter De Jonghe
Journal:  Dev Med Child Neurol       Date:  2011-04       Impact factor: 5.449

3.  Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations.

Authors:  James J Cox; Jony Sheynin; Zamir Shorer; Frank Reimann; Adeline K Nicholas; Lorena Zubovic; Marco Baralle; Elizabeth Wraige; Esther Manor; Jacov Levy; C Geoffery Woods; Ruti Parvari
Journal:  Hum Mutat       Date:  2010-09       Impact factor: 4.878

4.  Electrophysiological Differences between the Same Pore Region Mutation in SCN1A and SCN3A.

Authors:  Y-J Chen; Y-W Shi; H-Q Xu; M-L Chen; M-M Gao; W-W Sun; B Tang; Y Zeng; W-P Liao
Journal:  Mol Neurobiol       Date:  2014-07-03       Impact factor: 5.590

5.  SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis.

Authors:  Carla Marini; Ingrid E Scheffer; Rima Nabbout; Davide Mei; Kathy Cox; Leanne M Dibbens; Jacinta M McMahon; Xenia Iona; Rochio Sanchez Carpintero; Maurizio Elia; Maria Roberta Cilio; Nicola Specchio; Lucio Giordano; Pasquale Striano; Elena Gennaro; J Helen Cross; Sara Kivity; Miriam Y Neufeld; Zaid Afawi; Eva Andermann; Daniel Keene; Olivier Dulac; Federico Zara; Samuel F Berkovic; Renzo Guerrini; John C Mulley
Journal:  Epilepsia       Date:  2009-03-12       Impact factor: 5.864

6.  Nontruncating SCN1A mutations associated with severe myoclonic epilepsy of infancy impair cell surface expression.

Authors:  Christopher H Thompson; J Christopher Porter; Kristopher M Kahlig; Melissa A Daniels; Alfred L George
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

7.  A single-center, retrospective analysis of genotype-phenotype correlations in children with Dravet syndrome.

Authors:  Tracy S Gertler; Jeffrey Calhoun; Linda Laux
Journal:  Seizure       Date:  2019-12-13       Impact factor: 3.184

8.  Familial occurrence of febrile seizures and epilepsy in severe myoclonic epilepsy of infancy (SMEI) patients with SCN1A mutations.

Authors:  Maria Margherita Mancardi; Pasquale Striano; Elena Gennaro; Francesca Madia; Roberta Paravidino; Sara Scapolan; Bernardo Dalla Bernardina; Enrico Bertini; Amedeo Bianchi; Giuseppe Capovilla; Francesca Darra; Maurizio Elia; Elena Freri; Giuseppe Gobbi; Tiziana Granata; Renzo Guerrini; Chiara Pantaleoni; Antonia Parmeggiani; Antonino Romeo; Margherita Santucci; Marilena Vecchi; Pierangelo Veggiotti; Federico Vigevano; Angela Pistorio; Roberto Gaggero; Federico Zara
Journal:  Epilepsia       Date:  2006-10       Impact factor: 5.864

9.  Pitfalls in genetic testing: the story of missed SCN1A mutations.

Authors:  Tania Djémié; Sarah Weckhuysen; Sarah von Spiczak; Gemma L Carvill; Johanna Jaehn; Anna-Kaisa Anttonen; Eva Brilstra; Hande S Caglayan; Carolien G de Kovel; Christel Depienne; Eija Gaily; Elena Gennaro; Beatriz G Giraldez; Padhraig Gormley; Rosa Guerrero-López; Renzo Guerrini; Eija Hämäläinen; Corinna Hartmann; Laura Hernandez-Hernandez; Helle Hjalgrim; Bobby P C Koeleman; Eric Leguern; Anna-Elina Lehesjoki; Johannes R Lemke; Costin Leu; Carla Marini; Jacinta M McMahon; Davide Mei; Rikke S Møller; Hiltrud Muhle; Candace T Myers; Caroline Nava; Jose M Serratosa; Sanjay M Sisodiya; Ulrich Stephani; Pasquale Striano; Marjan J A van Kempen; Nienke E Verbeek; Sunay Usluer; Federico Zara; Aarno Palotie; Heather C Mefford; Ingrid E Scheffer; Peter De Jonghe; Ingo Helbig; Arvid Suls
Journal:  Mol Genet Genomic Med       Date:  2016-04-14       Impact factor: 2.183

10.  Novel and de novo mutations in pediatric refractory epilepsy.

Authors:  Jing Liu; Lili Tong; Shuangshuang Song; Yue Niu; Jun Li; Xiu Wu; Jie Zhang; Clement C Zai; Fang Luo; Jian Wu; Haiyin Li; Albert H C Wong; Ruopeng Sun; Fang Liu; Baomin Li
Journal:  Mol Brain       Date:  2018-09-05       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.